Fidelity, Arch support, RNAi emerging player City Therapeutics (CTY.US) aims for US IPO, plans to raise up to 185 millions dollars

智通财经2026/10/09 12:36

Show original

According to Jinse Finance, early-stage RNAi drug developer City Therapeutics Inc. (CTY.US) is seeking to raise up to 184.7 millions USD in its U.S. initial public offering (IPO). According to documents filed with the U.S. Securities and Exchange Commission on Friday, the company, whose investors include Arch Venture Partners and Fidelity Management & Research, plans to issue 9.72 million shares at a price range of $17 to $19 per share.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Dana Gas reports suspected drone attack on Iraq Kurdistan Khor Mor gas field, production halted

智通财经•2026/11/09 05:16

Earnings Preview | Applied Materials (AMAT.US) Q4 Results are Certain, the Real Focus is on the Missing 2027 Quantitative Guidance

Applied Materials' high growth in revenue and profit this quarter is already certain. What truly determines the stock price is the guidance for fiscal year 2027, changes in gross margin, and the marginal changes in China-related risks.

智通财经•2026/11/09 04:37

Earnings Preview | Applied Materials (AMAT.US) Q4 Results Hold No Surprises; The Real Focus Is the Yet-to-be-Given 2027 Quantitative Guidance

智通财经•2026/11/09 04:36

Nomura’s dominance is being challenged! Mizuho (MFG.US) is reshaping Japan’s underwriting landscape with global IPOs

智通财经•2026/11/09 03:51